Today: 27 February 2026
Subscribe
Browse Category

NYSE:AZN 16 September 2025 - 7 February 2026

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
7 February 2026
··
AstraZeneca stock price: NYSE switch, China bets and earnings put AZN in play this week

AstraZeneca stock price: NYSE switch, China bets and earnings put AZN in play this week

AstraZeneca shares closed in London at 135.48 pounds Friday, up 0.65%. The company moves its U.S. listing from Nasdaq to the NYSE on Monday, keeping the AZN ticker. AstraZeneca recently announced a $1.2 billion obesity drug deal with CSPC and pledged $15 billion investment in China by 2030. Investors await full-year results on Feb. 10.
1 February 2026
···
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.
31 January 2026
······
AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away

AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away

A U.S. appeals court on Friday revived a lawsuit accusing AstraZeneca and other firms of funding terrorism in Iraq. The ruling was announced after U.S. markets closed; AstraZeneca shares had closed up 1.37% in New York and 0.15% in London. The company plans to switch its U.S. listing from Nasdaq to NYSE on Jan. 30. Investors await Monday’s market reaction.
24 January 2026
··
AstraZeneca stock price slides as AZN sets Nasdaq exit, NYSE move dates

AstraZeneca stock price slides as AZN sets Nasdaq exit, NYSE move dates

AstraZeneca shares fell 4.4% to $90.23 Tuesday after the company said it will delist its American depositary shares from Nasdaq and move to a direct listing of ordinary shares on the NYSE starting February 2. The switch, set for after markets close January 30, comes as European stocks face pressure from U.S. tariff threats. AstraZeneca’s London shares also dropped 2.6%.
20 January 2026
···
Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI shares surged about 12% to $74.34 in Monday premarket trading after projecting 2025 revenue of $1.27 billion, up 83% from last year. The company reported total contract value over $1.1 billion and signed data deals with more than 70 clients, including major pharmaceutical firms. Northwestern Medicine announced a new partnership with Tempus to expand genomic cancer testing. Tempus’ figures remain preliminary and unaudited.
12 January 2026
······
Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI shares rose about 11% in premarket trading Monday after the company reported preliminary 2025 revenue of $1.27 billion, up 83% year-on-year, and record contract value exceeding $1.1 billion. The company cited strong growth in both Diagnostics and Data segments, with over 70 new data agreements signed in 2025. Tempus noted the results are unaudited and subject to change.
12 January 2026
·······
MSCI Europe vs World Indices: Performance, Forecasts and Key Drivers (5–7 December 2025)

MSCI Europe vs World Indices: Performance, Forecasts and Key Drivers (5–7 December 2025)

The MSCI Europe Index closed at 2,564.76 on Dec. 5, down 0.25% after a recent rally, but remains up about 12.5% to 15.5% year-to-date in 2025. The index outpaces the MSCI World, which is up roughly 7.7% for the year. European stocks continue to trade at lower valuations, with a 3.03% dividend yield and forward P/E of 14.64. The MSCI Europe Index has 402 constituents and a market cap near $12.85 trillion.
7 December 2025
···········
Salesforce Stock Pops as Q3 2026 Earnings, AI Deals and AstraZeneca Partnership Lift Guidance — But Investor AI Skepticism Lingers

Salesforce Stock Pops as Q3 2026 Earnings, AI Deals and AstraZeneca Partnership Lift Guidance — But Investor AI Skepticism Lingers

Salesforce reported Q3 FY26 revenue of $10.3 billion, up 9%, and adjusted EPS of $3.25, beating estimates. The company raised its full-year outlook, now projecting up to $41.55 billion in revenue and $11.77 adjusted EPS, citing strong demand for its AI products and the $8 billion Informatica acquisition. Remaining performance obligation rose 12% to $59.5 billion.
5 December 2025
·····
Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax shares surged 8% to $121.94 Thursday afternoon on heavy volume after fresh takeover rumors involving AstraZeneca. The French biotech’s stock is up about 1,450% year-to-date, fueled by strong Phase 3 ulcerative colitis data and M&A speculation. No deal has been confirmed by either company. Intraday volume reached 3.75 million ADSs, far above recent averages.
20 November 2025
··
Nasdaq Rally Amid Tech Frenzy: Markets Brush Off Shutdown Fears in Late September 2025

U.S. Stock Market Today (Nov. 6, 2025): Futures Mixed as Jobless Claims & Productivity Loom; Tesla Pay Vote, Airbnb & DraftKings Earnings in Focus

U.S. equity futures edged lower early Thursday as Asian markets rebounded on strong U.S. data, while European shares slipped. Treasury yields rose and the dollar stayed firm. Key U.S. data releases include jobless claims and productivity at 8:30 a.m. ET. Qualcomm, Arm, and Snap moved pre-market on earnings, with several major reports due before and after the bell.
6 November 2025
········
Stocks Rally to Record Highs as Shutdown Looms – Dow and S&P Post Best September in 15 Years

Stocks to Buy Today (Nov 6, 2025): ARM, AppLovin, Qualcomm, Tesla, Snap, AstraZeneca, Airbnb & More

The Federal Reserve cut rates by 25 basis points on Oct. 29, supporting growth and tech stocks. Arm Holdings reported Q2 revenue of $1.14 billion, up 34% year-over-year, and raised guidance on strong AI demand. AppLovin posted Q3 revenue of $1.405 billion and guided higher for Q4. Qualcomm beat Q4 estimates and issued an upbeat Q1 outlook despite a drop in shares.
6 November 2025
·······
European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

European stocks closed higher Monday, with the FTSE 100 up 0.5% and the STOXX 600 gaining 0.2% as healthcare and tech outperformed. GSK surged 3.3% after CEO Emma Walmsley’s exit was announced; AstraZeneca rose 1.3% on plans for a New York listing. Lufthansa said it will cut 4,000 jobs. Oil fell 0.6% on resumed Iraqi Kurdish exports and OPEC+ supply news; gold hit a record $3,812 an ounce.
29 September 2025
·······
Wall Street Braces for Shutdown: Stocks Rally as Fed Cuts Loom – Tech & Defense in Focus

Wall Street Braces for Shutdown: Stocks Rally as Fed Cuts Loom – Tech & Defense in Focus

S&P 500 futures rose 0.3% Monday as Congress faced a Tuesday midnight deadline to avert a U.S. government shutdown. Gold hit a record $3,808/oz, while oil slipped near $70 on OPEC+ news. AstraZeneca shares gained 1.3% on its NYSE listing plan; First Brands Group filed for Chapter 11. Investors trimmed Fed rate-cut bets amid mixed economic data and looming jobs report.
29 September 2025
·······
Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

U.S. inflation matched forecasts in August, with PCE up 0.3% from July and 2.7% year-on-year. Stocks rebounded, the S&P 500 and Dow rising about 0.5% by early afternoon. The White House announced new tariffs on drug imports, trucks, and furniture, effective Oct. 1. Treasury yields slipped, with the 10-year near 4.18% after the data release.
26 September 2025
·······
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly will invest $5 billion to build a 200,000-square-foot drug manufacturing plant in Goochland County, Virginia, creating 650 permanent jobs and 1,800 construction jobs. The facility will produce active pharmaceutical ingredients for cancer and autoimmune treatments. The project is part of Lilly’s $27 billion U.S. expansion plan. Virginia approved over $10 million in incentives to secure the site.
16 September 2025
·······
Go toTop